Risk Behaviors and Quality of Life in Women During Climacteric in Northwestern Mexico: A Humanistic Science Perspective
DOI:
https://doi.org/10.56294/saludcyt20252226Keywords:
Climacteric, Menopause, Quality of life, Risk factors, Women’s healthAbstract
Introduction: climacteric is a transitional stage in women’s lives, characterized by biological, psychological, and social changes that directly impact quality of life. In Mexico, this process is particularly relevant given the increasing number of women experiencing it and the need to understand its determinants from a holistic perspective.
Objective: to determine the factors and interrelationships that explain quality of life in women during climacteric in northwestern Mexico, adopting a humanistic science approach.
Methodology: an observational, descriptive, and cross-sectional study with correlational analysis and logistic regression was conducted. A sample of 380 women aged 45–60 years was selected through probabilistic stratified sampling at a Family Medicine Unit of the Mexican Institute of Social Security (IMSS) in Culiacán, Sinaloa. Data were collected using the CDP-9 form and the Menopause Rating Scale (MRS).
Results: unemployment and comorbidities significantly increased the likelihood of severe symptoms across somatic, psychological, and urogenital domains. Conversely, menstruation within the last 12 months acted as a protective factor in the psychological and urogenital dimensions. Multivariate models yielded AUC values ranging from 0,759 to 0,801, supporting their discriminative accuracy.
Conclusions: quality of life during climacteric emerges as a multidimensional phenomenon shaped by clinical and social determinants beyond hormonal decline. These findings highlight the need for integral and culturally sensitive interventions that address women’s physical, psychological, and social health simultaneously.
References
1. Organización Mundial de la Salud. Menopausia. [Internet]. 2023 [citado 2025 ago 10]. https://www.who.int/es/news-room/fact-sheets/detail/menopause
2. Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Edad de la menopausia e impacto de los síntomas climatéricos por región geográfica. Climacteric. 2010;13(5):419–28. https://doi.org/10.3109/13697137.2010.507886
3. Organización Panamericana de la Salud. OPS/OMS México participa en el Foro “La menopausia: un desafío de política pública[Internet]. 2023 mayo 17 [citado 2025 ago 10]. Disponible en: https://www.paho.org/es/noticias/17-5-2023-opsoms-mexico-participa-foro-menopausia-desafio-politica-publica
4. Instituto Nacional de Estadística y Geografía (INEGI). Panorama sociodemográfico de México. [Internet]. 2020 [citado 2025 ago 10]. Disponible en: https://www.inegi.org.mx/programas/ccpv/2020/tableros/panorama/
5. Gómez Ayala AE. Menopausia. Salud genitourinaria. Offarm. 2010;29(5):60–6. Disponible en: https://www.elsevier.es/es-revista-offarm-4-articulo-menopausia-salud-genitourinaria-X0212047X10556284
6. Urdaneta MJ, Cepeda de MV, Guerra MV, Baabel ZN, Contreras BA. Calidad de vida en mujeres menopáusicas con y sin terapia de reemplazo hormonal. Rev Chil Obstet Ginecol. 2010;75(1):17–34. https://doi.org/10.4067/S0717-75262010000100004
7. Organización Panamericana de la Salud. Menopausia y calidad de vida. [Internet]. 2023 [citado 2025 ago 10]. Disponible en: https://www.paho.org
8. Llango Lema KE, Céspedes Cueva JC. Calidad de vida de mujeres en etapa de menopausia. Salud Cienc Tecnol. 2022;2:78. https://doi.org/10.56294/saludcyt202278
9. Organización Mundial de la Salud. WHOQOL: Measuring Quality of Life[Internet]. 2023 [citado 2025 ago 10]. Disponible en: https://www.who.int/tools/whoqol
10. Cruz Martínez EA, Cruz Anguiano V, Martínez Torres J, Boo Vera D. Calidad de vida en mujeres durante su climaterio. Rev Fac Med UNAM. 2012;55(4):10–5. Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422012000400003
11. Sánchez Borrego R, García-García P, Mendoza N, Soler López B, Álamo González C. Evaluación de la calidad de vida en la mujer menopáusica mediante la escala Cervantes: impacto del tratamiento en la práctica clínica. Prog Obstet Ginecol. 2015;58(4):177–82. https://doi.org/10.1016/j.pog.2014.09.005
12. Tirado-Reyes RJ, Retamoza PL, Muñoz-Valencia NX, Acosta-Torres DE, Mendívil-Gastelum LV. Síndrome climatérico y funcionalidad familiar. Rev Enferm Inst Mex Seguro Soc. 2021;29(2):86–95. Disponible en: https://revistaenfermeria.imss.gob.mx/index.php/revista_enfermeria/article/view/1186
13. Resanovic I, Rizzo M, Zafirovic S, Bjelogrlic P, Perovic M, Savic K, et al. Anti-atherogenic effects of 17β-estradiol. Horm Metab Res. 2013;45(10):701–8. https://doi.org/10.1055/s-0033-1343478
14. Danser AH, Slump DE, Grefhorst A, van Veghel R, Garrelds IM, Roks AJ, et al. Angiotensin II type 2 receptor and acetylcholine-mediated relaxation: The essential contribution of female sex hormones and chromosomes. J Hypertens. 2015;33 Suppl 1:e115. https://doi.org/10.1097/01.hjh.0000467660.69156.d5
15. Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen effects on cognitive and synaptic health over the life course. Physiol Rev. 2015;95(3):785–807. https://doi.org/10.1152/physrev.00036.2014
16. Flores VA, Pal L, Manson JE. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Endocr Rev. 2021;42(6):720–52. https://doi.org/10.1210/endrev/bnab011
17. Martín-Aragón S, Benedí J. Terapia hormonal de reemplazo. Enfoque en la menopausia. Farm Prof. 2009;23(2):52–7. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-terapia-hormonal-reemplazo-enfoque-menopausia-13134176
18. Pérez Alcázar M. Menopausia. Transición. Farm Prof. 2002;16(9):88–95. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-menopausia-transicion-13038267
19. DePolo J. La NAMS publicó una declaración sobre la terapia no hormonal para los bochornos y el sudor nocturno. Breastcancer.org. 2023. Disponible en: https://www.breastcancer.org/es/noticias-de-investigacion/terapia-no-hormonal-bochornos
20. Deshmukh U, Khapre S, Jain S. Impact of soy isoflavone supplementation on menopausal symptoms in peri- and postmenopausal women. J Midlife Health. 2022;13(2):175–80. https://doi.org/10.4103/jmh.jmh_190_21
21. Ahsan M. The effect of soy isoflavones on menopausal rating scale score in peri- and postmenopausal women: A pilot study. J Clin Diagn Res. 2017;11(9):FC13–6. https://doi.org/10.7860/JCDR/2017/26034.10654
22. Tranche S, Brotons C, Pascual de la Pisa B, Macías R, Hevia E, Marzo-Castillejo M. Impact of a soy drink on climacteric symptoms: An open-label, crossover, randomized clinical trial. Gynecol Endocrinol. 2016;32(6):477–82. https://doi.org/10.3109/09513590.2015.1132305
23. Lambert MNT, Thorup AC, Hansen ESS, Jeppesen PB. Combined red clover isoflavones and probiotics potent reduction in menopausal vasomotor symptoms. PLoS One. 2017;12(6):e0176590. https://doi.org/10.1371/journal.pone.0176590
24. Carmignani LO, Pedro AO, Costa-Paiva LH, Pinto-Neto AM. Dietary soy supplementation versus estrogen and placebo on menopausal symptoms: A randomized controlled trial. Maturitas. 2010;67(3):262–9. https://doi.org/10.1016/j.maturitas.2010.07.007
25. Carmignani LO, Pedro AO, Montemor EB, Arias VA, Costa-Paiva LH, Pinto-Neto AM. Effects of a soy-based dietary supplement compared with low-dose hormone therapy on the urogenital system: A randomized, double-blind, controlled clinical trial. Menopause. 2015;22(7):741–9. https://doi.org/10.1097/GME.0000000000000404
26. Barnard ND, Kahleova H, Holtz DN, Znayenko-Miller TM, Sutton M, Holubkov R, et al. A dietary intervention for vasomotor symptoms of menopause: A randomized, controlled trial. Menopause. 2023;30(1):80–7. https://doi.org/10.1097/GME.0000000000002080
27. Ehsanpour S, Salehi K, Zolfaghari B, Bakhtiari S. The effects of red clover on quality of life in post-menopausal women. Iran J Nurs Midwifery Res. 2012;17(1):34–40. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590693/
28. Ribeiro AE, Monteiro NES, Moraes AVG de, Costa-Paiva LH, Pedro AO. Can the use of probiotics in association with isoflavone improve the symptoms of genitourinary syndrome of menopause? Menopause. 2019;26(6):643–52. https://doi.org/10.1097/GME.0000000000001306
29. Levis S. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: A randomized, double-blind trial. Arch Intern Med. 2011;171(15):1363–9. https://doi.org/10.1001/archinternmed.2011.330
30. Albert A, Altabre C, Baró F, Buendía E, Cabero A, Cancelo MJ, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: A multicentric, open, prospective and non-randomized trial. Phytomedicine. 2002;9(2):85–92. https://doi.org/10.1078/0944-7113-00104
31. Yoshikata R, Myint KZY, Ohta H, Ishigaki Y. Effects of an equol-containing supplement on advanced glycation end products, visceral fat and climacteric symptoms in postmenopausal women. PLoS One. 2021;16(9):e0257332. https://doi.org/10.1371/journal.pone.0257332
32. Drews K, Seremak-Mrozikiewicz A, Puk E, Kaluba-Skotarczak A, Malec M, Kazikowska A. Efficacy of standardized isoflavones extract (Soyfem) in moderate and medium-severe climacteric syndrome. Ginekol Pol. 2007;78(4):307–13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17621994/
33. Furlong ON, Parr HJ, Hodge SJ, Slevin MM, Simpson EE, McSorley EM, et al. Soy beverage consumption and cognitive function in postmenopausal women: A randomized trial. Eur J Nutr. 2020;59(2):755–66. https://doi.org/10.1007/s00394-019-01942-5
34. Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women. Maturitas. 2011;68(2):189–96. https://doi.org/10.1016/j.maturitas.2010.11.002
35. Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. 2011;93(2):356–67. https://doi.org/10.3945/ajcn.110.008359
36. Rattanatantikul T, Maiprasert M, Sugkraroek P, Bumrungpert A. Efficacy and safety of nutraceutical on menopausal symptoms in post-menopausal women: A randomized, double-blind, placebo-controlled clinical trial. J Diet Suppl. 2022;19(2):168–83. https://doi.org/10.1080/19390211.2020.1853648
37. Kim HI, Kim MK, Lee I, Yun J, Kim EH, Seo SK. Efficacy and safety of a standardized soy and hop extract on menopausal symptoms. J Altern Complement Med. 2021;27(11):959–67. https://doi.org/10.1089/acm.2021.0027
38. López-Ríos L, Barber MA, Wiebe J, Machín RP, Vega-Morales T, Chirino R. Influence of a new botanical combination on quality of life in menopausal Spanish women. PLoS One. 2021;16(7):e0255015. https://doi.org/10.1371/journal.pone.0255015
39. De Franciscis P, Conte A, Schiattarella A, Riemma G, Cobellis L, Colacurci N. Non-hormonal treatments for menopausal symptoms and sleep disturbances. Curr Pharm Des. 2020;26(35):4509–14. https://doi.org/10.2174/1381612826666200702165852
40. Díaz-Yamal I, Munévar-Vega L. Fitoestrógenos: Revisión de tema. Rev Colomb Obstet Ginecol. 2009;60(3):274–80. Disponible en: http://www.scielo.org.co/pdf/rcog/v60n3/v60n3a08.pdf
41. Zaheer K, Humayoun Akhtar M. An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health. Crit Rev Food Sci Nutr. 2017;57(6):1280–93. https://doi.org/10.1080/10408398.2014.989958
42. Luengo L, Tránsito M. Fitoestrógenos. Eficacia y seguridad. Offarm. 2010;29(3):86–90. Disponible en: https://www.elsevier.es/es-revista-offarm-4-articulo-fitoestrogenos-eficacia-seguridad-X0212047X10511945
43. Thangavel P, Puga-Olguín A, Rodríguez-Landa JF, Zepeda RC. Genistein as potential therapeutic candidate for menopausal symptoms and other related diseases. Molecules. 2019;24(21):3892. https://doi.org/10.3390/molecules24213892
44. Gray JR, Grove SK. Burns and Grove's the practice of nursing research: Appraisal, synthesis, and generation of evidence. 9th ed. St. Louis: Elsevier; 2020.
45. Heinemann K, Ruebig A, Potthoff P, Schneider HPG, Strelow F, Heinemann LAJ. The Menopause Rating Scale (MRS): A methodological review. Health Qual Life Outcomes. 2004;2:45. https://doi.org/10.1186/1477-7525-2-45
46. Jimenez Leyva IE, Nava Castañeda M de LA, Angulo Trizón G del C, Medina Serrano JM, Aguilar Lizarraga ME, Navarro Rodríguez DC, et al. Impact of phytoestrogen use on the quality of life of perimenopausal or postmenopausal women in Sinaloa, Mexico. Salud Cienc Tecnol. 2025;5:1095. https://doi.org/10.56294/saludcyt20251095
47. Cámara de Diputados del H. Congreso de la Unión. Reglamento de la Ley General de Salud en materia de investigación para la salud. [Internet]. México: Gobierno de México; 1987 [citado 2025 Ago 24]. Disponible en: https://www.diputados.gob.mx/LeyesBiblio/regley/Reg_LGS_MIS.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2025 María Guadalupe Navarrete Melgar, Roberto Joel Tirado Reyes, Dulce Samantha Ortíz Fonseca, Júlio Manuel Medina Serrano, Pedro Moisés Noh-Moo, Lubia del Carmen Castillo-Arcos (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
